Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1425-1432

  Flood, V H ^a,b   Gill, J C ^a,b,c   Christopherson, P A ^c   Wren, J S ^c   Friedman, K D ^c   Haberichter, S L ^a,b,c   Hoffmann, R G ^a   Montgomery, R R ^a,b,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Collagen; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN BINDING PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 6; RISTOCETIN; VON WILLEBRAND FACTOR;

AFRICAN AMERICAN; ARTICLE; BLEEDING; BLOOD GROUP; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

CASE-CONTROL STUDIES; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PROTEIN BINDING; PROTEIN ISOFORMS; VON WILLEBRAND DISEASES;

EID: 84863455676     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04747.x     Document Type: Article

References (28)

1. Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem 1987; 262: 13835-41.
2. Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermylen J. von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem J 1997; 324: 185-91.
3. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
4. Favaloro EJ. von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey. Semin Thromb Hemost 2002; 28: 191-202.
5. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83: 127-35.
6. Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease - single center comparison of four different assays. Thromb Haemost 2000; 84: 1127-8.
7. Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007; 33: 727-44.
8. Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006; 32: 514-21.
9. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
10. Rand JH, Patel ND, Schwartz E, Zhou SL, Potter BJ. 150-kD von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen. J Clin Invest 1991; 88: 253-9.
11. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116: 280-6.
12. Montgomery RR, Hathaway WE, Johnson J, Jacobson L, Muntean W. A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity. Blood 1982; 60: 201-7.
13. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111: 4979-85.
14. Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley AB, Evatt B. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003; 1: 2191-7.
15. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JW. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol 2005; 124: 910-7.
16. Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gill JC, Montgomery RR. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood 1996; 88: 2559-68.
17. Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009; 35: 60-75.
18. Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood 2009; 114: 1158-65.
19. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104: 1009-21.
20. Denis C, Baruch D, Kielty CM, Ajzenberg N, Christophe O, Meyer D. Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. Arterioscler Thromb 1993; 13: 398-406.
21. Rand JH, Glanville RW, Wu XX, Ross JM, Zangari M, Gordon RE, Schwartz E, Potter BJ. The significance of subendothelial von Willebrand factor. Thromb Haemost 1997; 78: 445-50.
22. Haley E, Babar N, Ritter C, Downes KA, Green D, Shurin S, Sarode R. Effect of ABO blood group on the collagen-binding assay for von Willebrand factor. Am J Hematol 2002; 71: 229-31.
23. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40.
24. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P, UK Haemophilia Centre Doctors' Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-41.
25. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 10: 112-21.
26. Mendelboum Raviv S, Szekeres-Csiki K, Jenei A, Nagy J, Shenkman B, Savion N, Harsfalvi J. Coating conditions matter to collagen matrix formation regarding von Willebrand factor and platelet binding. Thromb Res 2012; 129: e29-35.
27. Eikenboom J, van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 4: 774-82.
28. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.